OSO BIOPHARMACEUTICALS MANUFACTURING
OSO BIOPHARMACEUTICALS MANUFACTURING
Social Links:
Founded:
2008-01-01
Address:
Albuquerque, New Mexico, United States
Country:
United States
Website Url:
http://www.osobio.com
Total Employee:
251+
Status:
Active
Contact:
505-345-0500
Email Addresses:
[email protected]
Technology used in webpage:
SPF Domain Not Resolving Amazon GoDaddy DNS AWS Global Accelerator GoDaddy Premium DNS Cisco Ironport Cloud
Similar Organizations
Bionavigen
Bionavigen is a biopharmaceutical company.
Fiplate
Fiplate is a biopharmaceutical company.
Official Site Inspections
http://www.osobio.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Oso Biopharmaceuticals Manufacturing"
OrsoBio - Crunchbase Company Profile & Funding
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe …See details»
OrsoBio - Developing Therapies to Treat Metabolic …
The name OrsoBio is inspired by the remarkable metabolic adaptability of bears (“orso” in Italian) that enables them to avoid serious sequelae despite extreme environmental challenges before and during hibernation, including absence of …See details»
OsoBio at CMOLocator
Is this your Organization? Request Access. Locations. Albuquerque, NM 4401 Alexander Boulevard, NE Albuquerque, NM 87107 United States, North America. Contacts. Milton Boyer …See details»
About - Biopharmaceutical company targeting metabolic disorders - OrsoBio
OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies to address the underlying causes of organ dysfunction in patients with severe metabolic disorders. Our dedicated, highly skilled, and cohesive team of physicians and scientists bring decades of clinical and drug development experience, from academia and industry, that serves as the …See details»
OrsoBio Company Profile 2025: Valuation, Funding & Investors
OrsoBio General Information Description. Operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction. The company develops therapies to treat …See details»
OrsoBio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. OrsoBio . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. ... OrsoBio has 4 board members and …See details»
OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted ...
MENLO PARK, Calif. – June 21, 2024 (BUSINESS WIRE) – OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated …See details»
OrsoBio - Funding, Financials, Valuation & Investors - Crunchbase
Nov 2, 2022 OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders. Search Crunchbase. Start Free Trial . ... How much funding …See details»
OsoBio - Company Profile - Tracxn
Jan 1, 2025 OsoBio - CMO specializing in injectables and lyophilized biological and pharmaceutical products. Acquired by Curia. Raised funding from 1 investor. OsoBio has 172 …See details»
OrsoBio - Overview, News & Similar companies | ZoomInfo.com
Who is OrsoBio. OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies to address the underlying causes of organ dysfunction in patients with severe …See details»
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows ...
Sep 6, 2024 OrsoBio, an obesity-focused startup backed by Eli Lilly, has raised $67 million in a Series B funding round, the company announced Friday. The cash will help advance a …See details»
AMRI buys commercial manufacturer OsoBio for $110m
Jun 2, 2014 CMO (contract manufacturing organization) AMRI has agreed to acquire Oso Biopharmaceuticals Manufacturing for $110m in cash and thereby expand to late-stage and …See details»
AMRI to Acquire OsoBio - DCAT Value Chain Insights
Jun 2, 2014 “We are very excited about the synergies that our Albuquerque operations will bring to AMRI as part of its organization,” said Milton Boyer, OsoBio's president, in the release. “The …See details»
OrsoBio Announces Oversubscribed $67 Million Series B Financing …
Sep 6, 2024 MENLO PARK, Calif. – September 6, 2024 – OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and …See details»
OrsoBio, Inc. - Crunchbase Company Profile & Funding
OrsoBio, Inc. is located in Palo Alto, California, United States. Who are OrsoBio, Inc. 's competitors? Alternatives and possible competitors to OrsoBio, Inc. may include Cure Rare …See details»
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial ...
PALO ALTO, Calif.–(BUSINESS WIRE)– OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced completion …See details»
TLC-1180 - Drug Targets, Indications, Patents - Synapse
OrsoBio is conducting a Phase I trial of TLC-6740 in patients with obesity. Credit: New Africa/Shutterstock. Clinical-stage biopharmaceutical company OrsoBio has secured $67m in …See details»
AMRI CMO to Acquire OsoBio | Pharma Manufacturing
Jun 2, 2014 AMRI has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing (OsoBio) for $110 million in …See details»
OsoBio | Altaris, LLC
Jun 2, 2014 OsoBio President Milton Boyer to serve as vice president of DCAT’s executive committee Albuquerque, NM Dec 17, 2013 – OsoBio has reaffirmed its long-standing …See details»
OrsoBio - Updates, News, Events, Signals & Triggers - Crunchbase
Organization. OrsoBio . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Growth Insight Details. ... OrsoBio presented data on its liver-targeted mitochondrial protonophore TLC-6740 at the 84th Scientific Sessions of the American Diabetes Association. The presentation included Phase 1 and preclinical ...See details»